Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) have underperformed in the market recently due to various factors. Despite this, both companies offer potential opportunities and catalysts for long-term growth. Iovance Biotherapeutics saw success with its cancer medicine Amtagvi, generating $164.1 million in revenue last year. CRISPR Therapeutics, known for its gene-editing medicines, has yet to see significant revenue from its approved therapy Casgevy. Both stocks present opportunities for growth but also come with risks, making them more suitable for investors comfortable with volatility and potential long-term rewards.

Read more at Nasdaq: 2 Beaten-Down Stocks With Incredible Upside Potential